Weekly oral etoposide in patients with Kaposi's sarcoma associated with human immunodeficiency virus infection: a phase I multicenter trial of the AIDS Clinical Trials Group

Article Abstract:

Weekly doses of oral etoposide, an antineoplastic agent, can be given safely to AIDS patients with Kaposi's sarcoma (KS). Twenty-seven KS patients were treated with six once-at-week etoposide doses, which ranged from 150 to 400 mg, until unsatisfactory toxicity developed or the tumor advanced. Longer treatment was associated with toxicities, usually neutropenia, a decrease in neutrophilic leukocytes. Eight patients developed infections, which included bacterial pneumonia and pneumocystis carinii pneumonia. Stable responses were recorded in 14 patients or 56%. Among 25 patients who could be evaluated, partial tumor regression occurred in nine.

Health aspects, Care and treatment, Evaluation, Antineoplastic agents, Chemotherapy, Kaposi's sarcoma, Etoposide

---

Transgenic mouse models for HTLV-I infection

Article Abstract:

Experiments with transgenic mice have shown that the Tax protein of the human T cell leukemia virus type I (HTLV-I) is capable of transforming T cells into cancerous cells. This could explain how the virus causes adult T cell lymphoma/leukemia. Transgenic mice contain viral genes and are used as models of HTLV-I infection. These mice often develop tumors, lymphomas and leukemia. The Tax protein has also transformed cell lines in laboratory research. The protein activates genes that produce chemicals that stimulate immune cells, growth factors and other chemicals that activate genes.

Research, Models, HTLV-I infections, Genetically modified mice, Adult T-cell leukemia-lymphoma

---

Predictors of survival in HIV-infected persons with 50 or fewer CD4 cells/mm3

Article Abstract:

A very low CD4 lymphocyte count in patients with HIV indicates advanced infection, but may not predict imminent death. In patients with CD4 counts at or below 50 cells/mm3, low hemoglobin, male gender, Hispanic ethnicity, and symptomatic disease best predicted patients who would die.

United States, Statistical Data Included, Patient outcomes, Mortality, CD4 lymphocytes

Similar abstracts:

• Abstracts: Localized or systemic in vivo heat inactivation of human immunodeficiency virus (HIV): a mathematical analysis
• Abstracts: Vulvovaginal human papillomavirus infections: clinical implications and management. An evaluation of human papillomavirus testing for intermediate- and high-risk types as triage before colposcopy
• Abstracts: The new way to travel: renting a cottage. The best places to go, the best things to do in 1997. Bed-and-breakfasts versus hotels: pros, cons and which is right for you
• Abstracts: Complement activation and immune complexes in early congenital HIV infection. Diminished expression of cell-surface complement regulatory proteins in HIV-infected children and with HIV infection of peripheral blood mononuclear cells in vitro
• Abstracts: Polymerase chain reaction for the diagnosis of HIV infection in adults: a meta-analysis with recommendations for clinical practice and study design

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.